Ir para o conteúdo principal

United StatesÚltimas notícias

Grafa
Health

AstraZeneca, Daiichi reach key EU milestone for Enhertu expansion

The European Medicines Agency (EMA) has officially commenced its review of ENHERTU® (trastuzumab deruxtecan) in combination with pertuzumab, a move that could soon establish the antibody-drug conjugate (ADC) as a primary treatment for HER2-positive metastatic breast cancer in the European Union.

Leia mais: AstraZeneca, Daiichi reach key EU milestone for Enhertu expansion